| Company Name: |
ChemeGen
|
| Tel: |
18818260767 |
| Email: |
2625930290@qq.com |
| Products Intro: |
Product Name:Diprovocim-1
CAS:2170867-89-5
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
Diprovocim manufacturers
- Diprovocim-1
-
- $228.00
-
2026-07-27
- CAS:2170867-89-5
- Purity: 99.64%
- Supply Ability: 10g
|
| | Diprovocim Basic information |
| Product Name: | Diprovocim | | Synonyms: | Diprovocim;Diprovocim-1;3,4-Pyrrolidinedicarboxamide, 1,1'-(1,4-phenylenedicarbonyl)bis[N-[(1S,2R)-2-phenylcyclopropyl]-, (3S,3'S,4S,4'S)- | | CAS: | 2170867-89-5 | | MF: | C56H56N6O6 | | MW: | 909.1 | | EINECS: | | | Product Categories: | | | Mol File: | 2170867-89-5.mol |  |
| | Diprovocim Chemical Properties |
| density | 1.37±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | DMSO: soluble | | form | A solid | | pka | 14.18±0.40(Predicted) | | color | White to off-white | | InChIKey | ABZBNXFGYUSVCJ-UYMKNZQYSA-N |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | Diprovocim Usage And Synthesis |
| Uses | Diprovocim is a potent TLR1/TLR2 agonist. Diprovocim elicits full agonist activity in human THP-1 cells (EC50=110 pM). Diprovocim stimulates the release of TNF-α from mouse macrophages (EC50=1.3 nM). Diprovocim activates downstream MAPK and NF-κB signaling pathway. Diprovocim displays strong adjuvant activity in mice, particularly abetting cellular immune responses[1][2]. | | Biological Activity | Diprovocim-1 is an agonist of the toll-like receptor 1/2 heterodimer.1 It induces TNF-α release in THP-1 cells (EC50 = 110 pM), an effect that can be inhibited by anti-TLR1 or anti-TLR2 antibodies. Diprovocim-1 (10 mg/kg) increases the production of ovalbumin-specific IgG1 in wild-type, but not TLR2-/-, mice sensitized to ovalbumin.2 It also enhances anti-PD-L1 antibody-induced activation of cytotoxic T lymphocytes, reduction of tumor growth, and increases in survival in a B16/F10 murine melanoma model. | | in vivo | Diprovocim (10 mg/kg) uses as an adjuvant and mixed with ovalbumin (OVA; 100 μg) by i.m. induces similar levels of serum OVA-specific IgG after 14 days[2].
Diprovocim (10 mg/kg; i.m.) mixed with ovalbumin (OVA; 100 μg) before inoculation with B16-OVA cells immunizes significantly slows tumor growth rate but failed to prolong survival relative to OVA alone after 7 days[2].
| Animal Model: | WT or Tlr2/ C57BL/6J mice[2] | | Dosage: | 10 mg/kg | | Administration: | IM | | Result: | Induced similar levels of serum OVA-specific IgG, which were highly elevated compared with levels induced by immunization with OVA plus vehicle by i.m. with 100 μg OVA mixed with this drug.
|
| | IC 50 | TLR1; TLR2; p38 MAPK; NF-κB | | References | 1.Morin, M.D., Wang, Y., Jones, B.T., et al.Diprovocims: A new and exceptionally potent class of toll-like receptor agonistsJ. Am. Chem. Soc.140(43)14440-14454(2018)
2.Wang, Y., Su, L., Morin, M.D., et al.Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in miceProc. Natl. Acad. Sci. U.S.A.115(37)E8698-E8706(2018) |
| | Diprovocim Preparation Products And Raw materials |
|